FindTrial
Sign In

Assessing salivary and serum biomarker levels viz vascular endothelial growth factor (VEGF) in patients diagnosed with an autoimmune condition such as oral lichen planus.

Evaluation of salivary and serum vascular endothelial growth factor (VEGF) in patients with oral lichen planus: a comparative study. - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/12/060713
Enrollment
49
Registered
2023-12-26
Start date
Unknown
Completion date
Unknown
Last updated
2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L43- Lichen planus

Interventions

Intervention1: NIL: NIL Control Intervention1: NIL: NIL

Sponsors

Dr D Y Patil Dental College and Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: - Patients with Oral Lichen Planus diagnosed clinically and histopathologically - Patients above 18 years of age

Exclusion criteria

Exclusion criteria: - Patients under any current medical treatment - Patients having any other oral mucosal diseases

Design outcomes

Primary

MeasureTime frame
Salivary and serum Vascular endothelial growth factor levels can help diagnose and monitor oral lichen planus conditionTimepoint: baseline—

Secondary

MeasureTime frame
Salivary & serum Vascular endothelial growth factor levels can help diagnose & monitor oral lichen planus condition- 6 monthsTimepoint: baseline—

Countries

India

Contacts

Public ContactDr Amita Aditya

Dr. D.Y. Patil Dental College and Hospital

amita.aditya@dpu.edu.in9764003901

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026